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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.031We have previously identiﬁed osteoactivin (OA), encoded by Gpnmb, as an osteogenic factor that stimulates
osteoblast differentiation in vitro. To elucidate the importance of OA in osteogenesis, we characterized the
skeletal phenotype of a mouse model, DBA/2J (D2J) with a loss-of-function mutation in Gpnmb. Micro-
tomography of D2J mice showed decreased trabecular mass, compared to that in wild-type mice [DBA/2J-
Gpnmbþ/SjJ (D2J/Gpnmbþ)]. Serum analysis showed decreases in OA and the bone-formation markers
alkaline phosphatase and osteocalcin in D2J mice. Although D2J mice showed decreased osteoid and
mineralization surfaces, their osteoblastswere increased innumber, compared toD2J/Gpnmbþmice.We then
examined the ability of D2J osteoblasts to differentiate in culture, where their differentiation and function
were decreased, as evidenced by low alkaline phosphatase activity and matrix mineralization. Quantitative
RT-PCR analyses conﬁrmed the decreased expression of differentiation markers in D2J osteoblasts. In vitro,
D2J osteoblasts proliferated and survived signiﬁcantly less, compared to D2J/Gpnmbþ osteoblasts. Next, we
investigated whether mutant OA protein induces endoplasmic reticulum stress in D2J osteoblasts. Neither
endoplasmic reticulum stress markers nor endoplasmic reticulum ultrastructure were altered in D2J osteo-
blasts. Finally, we assessed underlying mechanisms that might alter proliferation of D2J osteoblasts.
Interestingly, TGF-b receptors and Smad-2/3 phosphorylation were up-regulated in D2J osteoblasts, sug-
gesting that OA contributes to TGF-b signaling. These data conﬁrm the anabolic role of OA in postnatal bone
formation. (Am J Pathol 2014, 184: 697e713; http://dx.doi.org/10.1016/j.ajpath.2013.11.031)Supported by the NIH (National Institute of Arthritis and Musculoskel-
etal and Skin Diseases grant R01-AR048892-06) and by a grant from the
Ohio Department of Development (F.F.S.).
Disclosures: None declared.Osteoporosis is a growing public health problem, in part
because of the increasing numbers of people living beyond
the age of 65 years.1 It is characterized by low bone mass
due to increased bone resorption by osteoclasts and de-
creased bone formation by osteoblasts, with signiﬁcant
deterioration in the bone microarchitecture leading to high
bone fragility and increased fracture risk.1,2 The net effect of
osteoporosis is low bone mass.1 There is an increasing de-
mand for identifying novel bone anabolic factors with po-
tential therapeutic beneﬁts in treating generalized bone loss,
such as osteoporosis and/or major skeletal fracture.
Osteoactivin is a novel glycoprotein ﬁrst identiﬁed in
natural mutant osteopetrotic rats.3 The same protein has
been identiﬁed and named separately in several other spe-
cies: as dendritic cell heparan sulfate proteoglycan integrin
dependent ligand (DCHIL) in mouse dendritic cells,4 as
transmembrane glycoprotein NMB (GPNMB) in humanstigative Pathology.
.melanoma cell lines and melanocytes,5 and as hematopoietic
growth factor inducible neurokinin (HGFIN) in human
tumor cells.6 The current recommended name for the protein
encoded by Gpnmb in mouse is transmembrane glycopro-
tein NMB (http://www.ncbi.nlm.nih.gov/protein/Q99P91.2);
here, we continue to use osteoactivin (OA) for the protein
and Gpnmb for the gene. OA is a type I transmembrane
protein that consists of multiple domains, including an
extracellular domain, transmembrane domain, and protein
sorting signal sequence.7 Within the C-terminal domain, OA
has an RGD motif, predicting an integrin attachment
site.3,7e9
Abdelmagid et alOur research group initially reported on the novel role of
OA in osteoblast differentiation and function.7e10 We
demonstrated that OA expression has a temporal pattern
during osteoblast differentiation, being highest during matrix
maturation and culture mineralization in vitro.7e11 Using
loss-ofefunction and gain-ofefunction approaches in osteo-
blasts, we reported that OA overexpression increases osteo-
blast differentiation and function and that OA down-regulation
decreases nodule formation, alkaline phosphatase (ALP) ac-
tivity, osteocalcin (OC) production, and matrix mineralization
in vitro.7 We also reported on the positive role of OA in
mesenchymal stem cell (MSCs) differentiation into osteoblasts
in vitro.12 In another study, we showed that recombinant OA
protein induces higher osteogenic potential of fetal-derived
MSCs, compared with bone marrowederived MSCs13 and
its osteogenic effects in the mouse C3H10T1/2 MSC cell line
were similar to those of recombinant BMP-2.12 We also
localized OA protein as associated predominately with oste-
oblasts lining trabecular bones in vivo,11 and showed that local
injection of recombinant OA increased bone mass in a rat
model.14 Moreover, in a fracture repair model OA expression
increased over time, reaching a maximum 2 weeks after
fracture.11 In a parallel study, recombinant OA supported bone
regeneration and formation in a rat critical-size calvarial defect
model.15 Others have shown that OA is highly expressed by
osteoclasts in vitro, suggesting that it may regulate osteoclast
formation and activity.16
There is urgent need for an animal model to fully examine
the role of OA in osteogenesis. Interestingly, a natural
mutation of the Gpnmb gene has been identiﬁed in the
DBA/2J (D2J) mouse strain.17 These mice exhibit high-
frequency hearing loss, which begins at the time of wean-
ing and becomes severe by 2 to 3 months of age.18,19 Aged
D2J mice also develop progressive eye abnormalities that
closely mimic human hereditary glaucoma. The onset of
disease symptoms falls roughly between 3 and 4 months of
age, and disease becomes severe by 6 months of age.5,20
D2J mice are homozygous for a nonsense mutation in the
Gpnmb gene sequence that induces an early stop codon,
generating a truncated protein sequence of 150 amino acids
(aa) instead of the full-length 562-aa OA protein.5 The
control for the D2J mouse is the wild-type DBA/2J-
Gpnmbþ/SjJ mouse (D2J/Gpnmbþ), homozygous for the
wild-type Gpnmb gene.21 These Gpnmb wild-type mice do
not develop glaucoma, as D2J mice do, although they
exhibit mild iris stromal atrophy.21
In the present study, we used Gpnmb mutant (D2J) and
Gpnmb wild-type (D2J/Gpnmbþ) mice to gain insight into
the role of OA in osteogenesis and in osteoblast differenti-
ation and function. Here, we report that loss-ofefunction
mutation of Gpnmb suppresses bone formation by directly
affecting osteoblast proliferation and survival, leading to a
decreased number of differentiated osteoblasts with sup-
pressed activity in bone mineralization. Thus, our data point
to OA as a novel and positive regulator of postnatal bone
formation.698Materials and Methods
Mice
Gpnmb-mutant DBA/2J mice (D2J) and mice of a control
strain [DBA/2J-Gpnmbþ/SjJ (D2J/Gpnmbþ)] with wild-type
Gpnmb alleles were obtained from the Jackson Laboratory
(Bar Harbor, ME). The DBA/2J-Gpnmbþ/SjJ strain was
generated by crossing DBA/2J-Dtnbp1sdy/J mice with mod-
ern D2J mice. DBA/2J-Dtnbp1sdy/J mice are D2J mice with a
mutation for sandy coat color that appeared in 1983, before
the appearance of the loss-ofefunction mutation in Gpnmb.
The strain has the wild-type Gpnmb alleles and has been
maintained as a separate strain since then. After crossing
DBA/2J-Dtnbp1sdy/J mice with D2J mice, the progeny were
selected for the Gpnmb wild-type alleles.21 The wild-type
allele was backcrossed to D2J for a minimum of six gener-
ations. Gpnmbþ is the ancestral D2J allele, and the homo-
zygous Gpnmb nonsense mutation is the only known genetic
difference between the D2J and D2J/Gpnmbþ strains.5
All mice were housed in cages containing white pine
bedding and covered with polyester ﬁlters. The environment
was kept at 21C with a 12-hour lightedark cycle. Mouse
colonies were maintained at Northeast Ohio Medical Uni-
versity in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC), under veterinary supervision and
according to the guidelines of the Institutional Animal Care
and Use Committee.
Micro-CT
Femurs from 4-, 8-, and 16-week-old male D2J and D2J/
Gpnmbþ mice (n  4 per group) were analyzed using a
SkyScan 1172 high-resolution microtomography (micro-
CT) system (Bruker, Billerica, MA). Trabecular measure-
ments of femurs were taken 400 mm below the distal growth
plate in 750 consecutive slices of 7.6-mm resolution over a
distance of 5700 mm, and volumetric regions were rendered
as three-dimensional arrays, using SkyScan NRecon soft-
ware. Percentage of bone volume per tissue volume [(BV/
TV)%], trabecular number (Tb.N; no./mm), trabecular
thickness (Tb.Th; mm), and trabecular separation (Tb.Sp;
mm) were measured and calculated using SkyScan CT
analyzer software. Three-dimensional reconstructed images
of the sagittal and axial planes of the femoral metaphysis
were generated using SkyScan CTvox software version 2.4.
Biochemical Analysis
Serum samples were prepared from 8- and 16-week-old
male D2J and D2J/Gpnmbþ mice (n  3 per group) that had
been fasted for 12 hours. Serum ALP (BIOTANG, Wal-
tham, MA), OC (Biomedical Technologies, Stoughton, MA)
and OA (R&D Systems, Minneapolis, MN) were measured
by enzyme-linked immunosorbent assay (ELISA) accordingajp.amjpathol.org - The American Journal of Pathology
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protein was quantiﬁed by ELISA in total protein isolated
from the calvaria of 8-week-old mice and from primary
osteoblast cultures. All ELISA data from serum, calvaria,
and cultures were normalized to the total mg protein con-
centration per sample using a Pierce bicinchoninic acid
protein assay kit (Thermo Fisher Scientiﬁc, Waltham, MA).
Tissue Preparation and Bone Histomorphometry
At necropsy, distal femurs from 8-week-old male D2J and
D2J/Gpnmbþmice (n 3 per group) were dissected, ﬁxed in
4% paraformaldehyde, dehydrated, and embedded unde-
calciﬁed in plastic methylmethacrylate resin. Sagittal sec-
tions (5 mm thick) were stained with von Kossaetoluidine
blue or Masson’s trichrome stain.22
Quantitative histomorphometry was performed in an area
from 100 mm to 600 mm proximal to the growth plate, using
OsteoMeasure software version 3.2.1 (Osteometrics, Deca-
tur, GA). Images were acquired with a brightﬁeld microscope
(Olympus, Center Valley, PA; Tokyo, Japan) equipped with
10 and 20 objectives and a digital color video camera with
a 0.7 reduction lens (Olympus 3CCD). Three-dimensional
and two-dimensional parametersweremeasuredand calculated
in three sections per animal. The three-dimensional parameters
were trabecular number [Tb.NZ (4/p) 0.5 (B.Pm/T.Ar)]
(no./mm) and trabecular separation [Tb.Sp Z (1/
Tb.N)  (1000  Tb.Th)] (mm). The two-dimensional pa-
rameters were trabecular number per tissue area (Tb.N/T.Ar),
bone perimeter per tissue area (B.Pm/T.Ar), osteoblast number
per bone perimeter (N.Ob/B.Pm), percentage of osteoblast
surface per bone surface [(Ob.S/B.S)%], percentage of osteoid
area per bone area [(O.Ar/B.Ar) %], osteoid width (O.Wi mm),
and osteoid maturation time [O.M.T, calculated as O.Wi/
mineral apposition rate (MAR) per day].
For dynamic histomorphometry, 8-week-old male D2J
and D2J/Gpnmbþ mice (n Z 4 per group) were injected
intraperitoneally with 10 mg/kg calcein AM (Thermo Fisher
Scientiﬁc) at 7 and 2 days before sacriﬁce. Femurs were
collected from euthanized mice, and histomorphometric
analysis of undecalciﬁed sections of the distal femur was
performed with transmitted and epiﬂuorescence microscopy
using a Nikon Eclipse Ti inverted microscope (Nikon,
Melville, NY; Tokyo, Japan). Single-labeled surface (sLS),
double-labeled surface (dLS), mineralizing surface [MS Z
dLS þ (sLS/2)], MAR (calculated using average dLS per
day), and bone formation rate (BFR, calculated as MAR 
MS) were measured and calculated.
Mouse Calvarial Osteoblast Cultures
Primary osteoblasts were isolated and cultured as described
previously.7e9 In brief, the calvaria from postnatal D2J and
D2J/Gpnmbþ mice at day 4 to 7 were isolated and digested
with 0.25% trypsin (Thermo Fisher Scientiﬁc) and 0.1%
collagenase B (Thermo Fisher Scientiﬁc) for ﬁve cycles (20The American Journal of Pathology - ajp.amjpathol.orgminutes/cycle) at 37C. Only cells from digests 2 to 5 were
collected. Cells were plated at a density of 2  104 cells/cm2
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Thermo
Fisher Scientiﬁc) and cultured until conﬂuent. Cells were
then maintained in DMEM containing 10% fetal bovine
serum (FBS) (HyClone; Thermo Fisher Scientiﬁc), 100 IU/
mL penicillin, 100 mg/mL streptomycin (HyClone), and 25
ng/mL amphotericin B (HyClone). For osteoblast differen-
tiation, cells were cultured in minimum essential medium a
(HyClone) supplemented with 10% FBS, 50 mg/mL ascorbic
acid, and 10 mmol/L b-glycerophosphate (Thermo Fisher
Scientiﬁc). The medium was changed every 2 to 3 days.
Adult Mouse Long-Bone Osteoblast Cultures
Primary osteoblasts were isolated and cultured as described
previously.23 In brief, femurs and tibias from 8-week-old D2J
and D2J/Gpnmbþ mice were dissected, epiphyses were cut
off, and bonemarrowwasﬂushed out. The diaphyseswere cut
into small pieces and digested with 0.2% collagenase B for 2
hours at 37C. Bone pieces were transferred to 10-cm culture
dishes at a density of 20 to 30 fragments per dish. Adult mouse
bone cells migrate from the bone chips after approximately 5
days. Cells were trypsinized and replated at a density of
2  104 cells/cm2 in DMEM and cultured until conﬂuent.
Cells were then maintained in DMEM containing 10% FBS,
100 IU/mL penicillin, 100 mg/mL streptomycin, and 25 ng/
mL amphotericin B. For osteoblast differentiation, cells were
cultured in minimum essential medium a supplemented with
10% FBS, 50 mg/mL ascorbic acid, and 10 mmol/L b-glyc-
erophosphate. The medium was changed every 2 to 3 days.
ProliferationeApoptosis and Survival Assays
Primary osteoblasts from the calvaria of neonatal D2J and
D2J/Gpnmbþ mice or from long bones of adult D2J and
D2J/Gpnmbþ mice were cultured in 96-well plates (6  103
cells/cm2) in DMEM supplemented with 10% FBS in 96-
well plate and total DNA content was measured after 24,
48, and 72 hours, using a CyQUANT NF cell proliferation
assay kit (Life Technologies, Carlsbad, CA) according to
the manufacturer’s protocol. In brief, medium was removed
and replaced with 100 mL 1 dye binding solution and
incubated at 37C in for 1 hour in the dark. Sample ﬂuo-
rescence intensity was measured using BioTek Synergy H4
microplate reader (BioTek Instruments, Winooski, VT) with
excitation at 485 nm and emission detection at 530 nm.
In parallel experiments, osteoblasts were treated with
DMEM supplemented with 10% serum isolated from 8-
week-old D2J or D2J/Gpnmbþ mice (nZ 3 per group), and
total DNA content was measured after 24 hours as described
above. For cell apoptosis assay, primary osteoblasts from
the calvaria of neonatal D2J and D2J/Gpnmbþ mice were
cultured in 96-well plates (1  104 cells/cm2) in DMEM
with 10% FBS; serum was then reduced to 2.5% for 24, 48,
or 72 hours of culture, and cell apoptosis was measured699
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brief, medium was removed and replaced with 100 mL of
Caspase-Glo 3/7 reagent and cells were incubated at room
temperature for 3 hours in the dark. Luciferase reaction was
measured using a BioTek Synergy H4 microplate reader
(BioTek Instruments) with excitation at 485 nm and emis-
sion detection at 530 nm.
For cell survival assay, primary osteoblasts were cultured
in 96-well (1  104 cells/cm2) in DMEM with 10% FBS
and then were treated with tunicamycin (5 mg/mL) (Sigma-
Aldrich, St. Louis, MO) and cell survival was measured
using MTT assay. In brief, medium was removed and
replaced with 1.2 mmol/L MTT substrate (Sigma-Aldrich)
in 1 Hanks’ balanced salt solution, and cells were then
incubated at 37C for 4 hours in the dark. MTT working
reagent was removed, and formazan crystals were dissolved
in 100 mL dimethyl sulfoxide. Absorbance of the colori-
metric reaction was measured at 540 nm.
Immunoﬂuorescence Staining
Primary osteoblasts from the calvaria of neonatal D2J and
D2J/Gpnmbþmice were cultured in four-well chamber slides
(1  103 cells/cm2) for 48 hours, ﬁxed in situ with 4%
paraformaldehyde for 20 minutes, washed in PBS, per-
meabilized with 0.5% Triton X, and incubated with anti-
mouse OA polyclonal primary antibody (R&D Systems)
and/or anti-calnexin monoclonal antibody [a marker of rough
endoplasmic reticulum (rER)] (BD Biosciences, San Jose,
CA) overnight in a humidiﬁed chamber at 4C. Cells were
then washed and incubated with Cy2-conjugated secondary
goat anti-mouse OA antibody and/or Cy3-conjugated sec-
ondary goat anti-mouse calnexin antibody (Molecular Probes;
Life Technologies, Carlsbad, CA). Nuclei were labeled using
Fluoroshield mounting medium with DAPI (Abcam, Cam-
bridge, MA). Fluorescence images were captured with a
Nikon Eclipse Ti inverted microscope using a 490-nm exci-
tation ﬁlter for OA (green), a 550-nm excitation ﬁlter for
calnexin (red), and a 350-nm excitation ﬁlter for DAPI (blue).
Transmission Electron Microscopy
Primary osteoblasts from calvaria of neonatal D2J and D2J/
Gpnmbþ mice were cultured in DMEM (no b-glycer-
ophosphate) in Petri dishes for 10 days, pelleted down, and
ﬁxed in situ for 1 hour at 4C in 2% glutaraldehyde in 0.1
mol/L sodium cacodylate buffer (pH 7.4). Specimens were
washed overnight with 7% sucrose buffer, postﬁxed for 1
hour in 2% osmium tetroxide in 0.1 mol/L sodium caco-
dylate buffer (pH 7.4), and stained en bloc for 30 minutes
with 0.1% aqueous uranyl acetate. After dehydration, cell
pellets were transferred into glass vials, washed with pro-
pylene oxide, and embedded in Spurr’s resin. For long
bones, femurs from 8-week-old D2J and D2J/Gpnmbþ were
ﬁxed and embedded in Spurr’s resin. Ultrathin bone sections
(2 mm) or cell pellets were stained with uranyl acetate and700lead citrate before examination with a Philips CM10 trans-
mission electron microscope (FEI, Hillsboro, OR).
Quantiﬁcation of Osteoblast Matrix Formation
Matrix maturation in osteoblast cultures was determined by
ALP staining and activity7,9 and matrix collagen staining.
ALP staining was performed for calvarial osteoblasts at day
14, using an ALP staining kit (Sigma-Aldrich) according to
the manufacturer’s instructions. ALP-positive cells were
stained purple. In parallel wells, ALP activity was determined
in total cell lysates using an ALP activity kit (BioAssay
Systems, Hayward, CA) according to the manufacturer’s
protocol. In brief, 50 mL of cell lysate was added to 150 mL of
working solution, and optical density absorbance was
measured at 405 nm at 0 and 4 minutes. ALP activity was
calculated in enzyme units (UZ mmol/L, per minute) per mg
protein. For collagen, parallel culture wells were ﬁxed in 4%
paraformaldehyde and stained for collagen with Sirius Red
(0.1% in saturated picric acid) for 30 minutes on a shaker at
room temperature, washed twice in PBS, and air dried.
Stained wells were scanned at 2400 dpi, and quantiﬁcation of
collagen staining was performed using ImageJ software
version 1.48p (NIH, Bethesda, MD). The incorporated dye
was extracted in 0.2 mol/L of sodium hydroxide in methanol
(v/v) for 30 minutes with agitation, and 200 mL samples were
read in a microplate reader at 490 nm. Data were normalized
to the total protein concentration of each sample.
Quantiﬁcation of Osteoblast Matrix Mineralization
Mineralized matrix in osteoblast cultures was determined by
Alizarin Red S, calcium assay, and von Kossa staining as
described previously.7,9 To visualize mineralized matrix at
day 21, osteoblast cultures were stained with Alizarin Red S
(40 mmol/L, pH 4.2) for 15 minutes and then were washed
with distilled water. The incorporated dye was extracted in
10% (v/v) acetic acid, heated at 85C for 10 minutes,
centrifuged at 20,000  g for 15 minutes, and neutralized
with 10% (v/v) ammonium hydroxide. Optical density was
then measured at 405 nm. In parallel wells, total calcium was
determined in mineralized matrix lysed with 0.5 mol/L HCl
using a QuantiChrom calcium assay kit (BioAssay Systems)
according to the manufacturer’s instructions. In brief, 5 mL of
cell lysates was added to 200 mLworking solution and optical
density was measured at 570 nm. Data were normalized to the
total protein concentration of each sample.
To visualize mineralized nodules, parallel osteoblast cul-
tures were stained at day 21 with von Kossa stain. In brief,
cultures were stained with 5% silver nitrate solution under
exposure toUV light for 20minutes and thenwerewashedwith
distilled water. Mineralized nodules were stained black for
hydroxyapatite crystals and ﬁxed with 5% sodium thiosulfate.
Mineralized nodule count and size were measured using live-
imaging Nikon Ti Eclipse microscopy with automated object
capture using NIS-Elements software version 4.10.1.ajp.amjpathol.org - The American Journal of Pathology
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Total proteins were isolated from primary osteoblast cultures
and subjected to SDS-PAGE electrophoresis as described
previously.9 In brief, cells were lysed in radioimmuno-
precipitation assay buffer (EMD Millipore, Billerica, MA),
and protein concentration was measured using a Pierce
bicinchoninic acid protein assay kit (Thermo Fisher Scienti-
ﬁc). Protein samples (25 mg) were mixed with denaturing
buffer, heated to 100C, and subjected to 10% SDS-PAGE in
1Tris-glycineeSDS running buffer for 90minutes. The gel
was then transferred to a nitrocellulose membrane using a
semidry transfer apparatus (Bio-Rad Laboratories, Hercules,
CA) for 5 minutes. The blot was incubated in blocking buffer
(5% nonfat milk in Tris-buffered saline) for 7 minutes using a
SNAP i.d. protein detection system (EMDMillipore) and then
was probed for OA (R&D Systems), GRP-78 (Thermo Fisher
Scientiﬁc), TGF-b1 (Bioss, Woburn, MA), TGF-b receptor II
(Bioss), and p-Smad-2 and p-Smad-3 (Cell Signaling Tech-
nology, Danvers, MA), in blocking buffer overnight at 4C.
Next, the blot was washed in 1 Tris-buffered saline/Tween
20 (TBST) and incubated with anti-rabbit IgG horseradish
peroxidaseeconjugated secondary antibody (R&D Systems)
for 1 hour. The blot was then washed in TBST and incubated
with Pierce chemiluminescent substrate (Thermo Fisher Sci-
entiﬁc). Signals were detected using an ImageQuant LAS
4000 digital imaging system (GEHealthcare, Piscataway, NJ;
Little Chalfont, UK). The blots were stripped brieﬂy, washed
in TBST, and reprobed for Smad-2, Smad-3, and actin.
RT-qPCR
For quantitative real-time RT-PCR (RT-qPCR), total RNA
was extracted from calvaria, tibia, or primary osteoblasts of
8-week-old D2J and D2J/Gpnmbþ mice (n  3 per group),
using TRIzol reagent (Life Technologies) and a SurePrep
RNA extraction kit (Thermo Fisher Scientiﬁc). RNA
quantities were measured using a NanoDrop 2000 spectro-
photometer (Thermo Fisher Scientiﬁc). cDNA was prepared
using a high-capacity cDNA reverse transcription kit (Life
Technologies). qPCR was performed with an ABI 7500 Fast
real-time PCR system (Life Technologies) in duplicate
20-mL reactions, each containing 10 ng cDNA reaction mix,
100 nmol/L of each primer, and 10 mL 2 SYBR Green
PCR master mix (Life Technologies). qPCR cycles con-
sisted of an initial cycle of 50C for 2 minutes, a second
cycle of 95C for 10 minutes, and then 40 cycles of 95C for
15 seconds and 60C for 1 minute. Using GAPDH as the
internal control, relative gene expression among samples
was calculated by comparison of CT values. A dissociation
curve was checked for each qPCR run, to conﬁrm speciﬁc
ampliﬁcation of target RNA. All qPCR mouse primers were
purchased from Qiagen (Valencia, CA): proliferation cell
nuclear antigen (PCNA), apoptosis regulator Bax, Runx2,
Msx2, ALP, collagen type I (Col1), OC, OA, TGF-b1,
TGF-b receptors I and II, and GAPDH.The American Journal of Pathology - ajp.amjpathol.orgOsteogenesis Array
Total RNA was isolated from the calvaria of 8-week-old
D2J and D2J/Gpnmbþ mice using TRI Reagent (Sigma-
Aldrich). After DNase treatment, RNA was further cleaned
using an RNeasy mini kit (Qiagen). cDNA was synthesized
using an RT2 First Strand kit (SABiosciences; Qiagen,
Valencia, CA) according to the manufacturer’s instructions.
Gene expression proﬁling was performed using a mouse
osteogenesis RT2 Proﬁler PCR array (SABiosciences; Qia-
gen). This platform is designed to proﬁle the gene expres-
sion of 84 key osteogenesis-associated genes. RT-qPCR
was performed using an ABI 7500 Fast real-time PCR
system (Life Technologies) according to the array manu-
facturer’s instructions. Relative gene expression was deter-
mined using the DDCT method. Data were further analyzed
with the SABiosciences PCR array data analysis web portal
(http://www.SABiosciences.com/pcrarraydataanalysis.php).
Statistical Analysis
For all quantitative data generated, differences between in-
dividual groups were analyzed for statistical signiﬁcance
using GraphPad Prism software version 5.04 (GraphPad
Software, La Jolla, CA). In most cases, when the data fol-
lowed a normal distribution, one-factor or two-factor analysis
of variance was performed, followed by a Bonferroni post
hoc test. For comparisons between two group means, an
unpairedet-test was performed. Differences were considered
statistically signiﬁcant at P < 0.05. All in vitro experiments
were repeated (n  3) with three replicates per experiment.
Results
Loss-ofeFunction Mutation in Gpnmb Reduces Bone
Formation
Having previously identiﬁed the role of OA in osteoblast
differentiation and function in vitro,7e9,11 in the present
study we evaluated the role of OA in bone formation in vivo,
using a mouse model, D2J, with natural nonsense mutation
of Gpnmb, compared with the D2J/Gpnmbþ wild type.
Micro-CT of trabecular bone at 4 weeks of age showed a
signiﬁcant decrease in bone mass in D2J mice, compared to
D2J/Gpnmbþ (Figure 1A). (Hereafter, if no other contrast is
speciﬁed, differences reported for D2J mice are relative to
D2J/Gpnmbþ mice.) Trabecular number was also signiﬁ-
cantly decreased in D2J mice, whereas trabecular separation
was increased (Figure 1, B and C). At 8 weeks of age,
micro-CT of the femoral metaphysis showed increased
width of femoral metaphysis and consistent decrease of
trabecular mass in D2J mice (Figure 1, D and E). Trabecular
volume was decreased by approximately 60% in D2J mice
(Figure 1F), and trabecular number was decreased by
approximately 50% (Figure 1G), but trabecular separation
was increased (Figure 1H).701
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mice, compared to D2J/Gpnmbþ mice, we performed micro-
CT of the femoral metaphysis at 16 weeks of age, when
mice reach skeletal maturity. Consistent with the above data,
our ﬁndings showed signiﬁcant decrease in bone volume
and trabecular number in D2J, while trabecular separation
was increased (Figure 1, IeK). Two other micro-CT pa-
rameters, trabecular thickness and trabecular surface, were
consistently decreased in D2J mice at 4, 8, and 16 weeks of
age; however, trabecular surface as a percentage of bone
volume was increased in D2J mice, because of marked
decrease in bone volume (Table 1).
Next, we determined the levels of OA protein in 8-week-
old D2J and D2J/Gpnmbþ mice. ELISA showed that OAFigure 1 Micro-CT analysis of femur in 4-week-old (AeC), 8-week-old (FeH), and1
and I), Tb.N (B, G, and J), and Tb.Sp (C,H, andK). D and E: Representative three-dimen
the femoralmetaphysis,with thecorresponding three-dimensional trabecularplatewith
(AeC), nZ 5 (IeK), and n  8 (FeH) mice per group. *P < 0.05, **P < 0.01, and
702protein in serum and calvaria of D2J mice was decreased by
approximately 50% (Figure 2, A and B). To test the role of
OA in osteogenesis in D2J and D2J/Gpnmbþ mice, we
performed serum ELISA of the bone-formation markers
ALP and OC; both markers showed a decrease of 50% or
more at 8 weeks in D2J mice (Figure 2, C and D). Serum
ELISA of OC showed similar results at 16 weeks (data not
shown). These data suggest that OA plays a role in bone
formation. Next, we examined two bone-remodeling
markers, receptor activator of nuclear factor k-B ligand
(RANKL) and osteoprotegerin (OPG). RANKL is well
known to stimulate osteoclastogenesis, and OPG is reported
to be a decoy receptor for RANKL.24,25 Interestingly, serum
ELISA revealed no signiﬁcant difference in RANKL, OPG,6-week-old (IeK) D2Jmutant andD2J/Gpnmbþwild-typemice for BV/TV (A, F,
sional micro-CTereconstructed image of the sagittal (D) and axial (E) planes of
out cortical bone in 8-week-oldmice. Data areexpressedasmeans SEM.nZ4
****P < 0.0001.
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Table 1 Micro-CT Analyses in D2J Mutant and D2J/Gpnmbþ Wild-Type Mice
Age (wk) Genotype Tb.Th (mm) B.S/TV (mm2/mm3) B.S/BV (mm2/mm3)
4 D2J/Gpnmbþ 17.78  0.39 8.27  0.18 111.7  2.23
D2J 16.37  0.34* 7.38  0.27* 121  2.83*
8 D2J/Gpnmbþ 23.87  0.81 19.36  1.61 84.75  3.14
D2J 17.03  0.36**** 9.8  0.24**** 117.8  2.51****
16 D2J/Gpnmbþ 21.22  0.67 12.52  0.6 99.07  3.07
D2J 17.12  1.23** 10.07  0.47** 119.0  78**
Data are expressed as means  SEM.
*P < 0.05, **P < 0.01, and ****P < 0.0001 versus wild type.
B.S/TV, bone surface per tissue volume; B.S/BV, bone surface per bone volume; Tb.Th, trabecular thickness.
Gpnmb Mutation Decreases Bone Formationand the RANKL/OPG ratio between D2J and D2J/Gpnmbþ
mice (Figure 2, EeG).
To further investigate the importance of OA in bone
microstructure, we performed histomorphometric analyses
of the femoral metaphysis in 8-week-old D2J and D2J/
Gpnmbþ mice. The width of the femoral metaphysis was
increased and trabecular bone mass was decreased in D2J
mice (Figure 3A), in accord with the data reported above.
Moreover, our analysis indicated an approximately 35%Figure 2 Analysis of OA and bone remodeling markers in D2J and D2J/
Gpnmbþ mice. A and B: ELISA of OA protein in serum (A) and homogenized
calvarial bone (B) of D2J and D2J/Gpnmbþ mice. CeG: Serum ELISA of the
bone formation markers ALP (C) and OC (D) and the bone resorption
markers RANKL (E) and OPG (F), along with the RANKL/OPG ratio (G). Data
are expressed as means  SEM. n  3 (A and B) and n  4 (CeG).
*P < 0.05, **P < 0.01, and ***P < 0.001.
The American Journal of Pathology - ajp.amjpathol.orgdecrease in trabecular number (Figure 3B) and an approxi-
mately 45% increase in trabecular separation in D2J mice
(Figure 3C). Furthermore, trabecular number and bone
perimeter as a percentage of tissue area were also decreased
in D2J mice (Figure 3, D and E). Although these ﬁndings
support the positive role of OA in bone formation, we also
observed a surprising increase (approximately 60%) in oste-
oblast number and surface in D2J mice (Figure 3, F and G).
Next, we examined the importance of OA in osteoid
matrix formation and mineralization in D2J and D2J/
Gpnmbþ mice. Histological analysis of femoral metaphysis
showed a decrease in trabecular osteoid width in D2J mice
(Figure 3H). Moreover, histomorphometric analysis showed
approximately 40% decrease in trabecular osteoid as a
percentage of bone area in D2J mice (Figure 3I). In addition,
osteoid maturation time, a parameter that detects any subtle
impairment in bone mineralization, was approximately 50%
prolonged in D2J mice (Figure 3J). Bone dynamic analyses
showed decreased bone mineralization associated with
decreased width of interlabeled surfaces in D2J mice
(Figure 3K). These ﬁndings were conﬁrmed by the signiﬁ-
cant decrease in mineral apposition and bone formation rates
in D2J mice (Figure 3, L and M). Taken together, these data
suggest that OA is a positive regulator of bone formation
and osteoblast function in vivo.
Defective Osteoblast Differentiation in D2J Mice
In our previous studies, using loss-ofefunction and gain-
ofefunction approaches, we showed the importance of OA
in osteoblast differentiation and function in vitro.7 In the
present study, we characterized osteoblast differentiation in
D2J and D2J/Gpnmbþ mice. First, we compared the pro-
duction of the OA protein in osteoblasts. Western blotting
showed OA glycoprotein present in D2J/Gpnmbþ osteo-
blasts, but not in D2J osteoblasts (Figure 4A). A low mo-
lecular weight protein (approximately 15 kDa) detected in
D2J osteoblasts may correspond to the mutant truncated OA
protein of 150 aa (see below). Quantitation of OA protein in
cultured osteoblasts showed an approximately 70% decrease
in production of OA protein by D2J osteoblasts (Figure 4B).
To evaluate the importance of OA in osteoblast differ-
entiation ex vivo, we determined the expression of two early
matrix markers, ALP and Col1, in differentiated D2J and703
Figure 3 Histomorphometric analysis of femurs of D2J and D2J/Gpnmbþ mice. A: Sagittal sections with von Kossa staining for minerals (black) and
toluidine blue counterstain show adipocytes (green asterisks), periosteum (red asterisks), trabecular bone (red arrows), and osteoid (yellow arrows). BeG:
Histomorphometric parameters Tb.N (B), Tb.Sp (C), Tb.N/T.Ar (D), B.Pm/T.Ar (E), N.Ob/B.Pm (F), and Ob.S/B.S (G). H: Sagittal sections stained with Masson’s
trichrome show osteoid (red) (black arrows, middle panel); thickness of osteoid (red) is indicated with paired yellow arrows (right panel). I and J:
Histomorphometric parameters: O.Ar/B.Ar (I) and O.M.T (J). K: Calcein AM labeling for mineralized bone surface (green) shows periosteum (asterisks) and
mineralized bone width (double-headed arrows). L and M: Dynamic histomorphometric parameters MAR (L) and BFR/B.Ar (M). Data are expressed as
means  SEM. nZ 4 (L and M); nZ 5 (BeG); nZ 6 (I and J). *P < 0.05, **P < 0.01. Scale bars: 200 mm (A and H, left); 50 mm (A and H, middle); 25 mm
(A and H, right); and 25 mm (K).
Abdelmagid et alD2J/Gpnmbþ osteoblasts at day 14. Both ALP staining and
ALP activity were decreased in D2J osteoblasts (Figure 4, C
and D). Next, we examined whether mutant OA protein has
any effects on Col1 production by osteoblasts. We observed
decreased staining in D2J mice, and Col1 ﬁbers were
randomly organized, in contrast to the well-oriented Col1
ﬁbers surrounding osteoblast nodules in D2J/Gpnmbþ mice
(Figure 4E). Moreover, quantiﬁcation and percentage area
fraction of Col1-stained matrix were signiﬁcantly less in
D2J mice (Figure 4, F and G).
To further investigate the role of OA in later osteoblast
differentiation and function, we differentiated D2J and D2J/
Gpnmbþ osteoblasts and analyzed matrix mineralization
markers, calcium deposition, and nodule formation at day 21.
We observed decreased matrix mineralization (Figure 5A) in
D2J mice, as indicated by an approximately 25% decrease in
quantiﬁcation of calcium-stained matrix (Figure 5B) and
approximately 50% less calcium deposition (Figure 5C).
Next, we examined the mineralized nodules in D2J and D2J/
Gpnmbþmatrix. Nodule formation andmatrix mineralization
were decreased (Figure 5D), as indicated by approximately
75% decrease in number and size of mineralized nodules in704D2J matrix, (Figure 5, E and F). Collectively, these data
support a signiﬁcant role for OA during different stages of
osteoblast differentiation and matrix mineralization.
We then compared our ﬁndings for osteoblast differentia-
tion with markers of osteogenesis. First, we used qPCR to
quantitate the expression of Gpnmb encoding OA in D2J and
D2J/Gpnmbþ osteoblasts differentiated for 7, 14, and 21 days.
We observed a temporal increase in Gpnmb expression in
osteoblasts of D2J/Gpnmbþ mice, with a maximum at day 21,
but Gpnmb expression was greatly decreased in D2J osteo-
blasts, compared to D2J/Gpnmbþ osteoblasts, at each time
point (Figure 6A). Next, we examined the osteoblast differ-
entiation markers ALP, Col1, and OC. qPCR analysis of ALP
showed decreased expression inD2J osteoblasts mice at days 7
and 14 (Figure 6B). Moreover, Col1 gene expression was also
decreased in D2J osteoblasts at day 7 (Figure 6C). Interest-
ingly, OC gene expression was approximately 80% decreased
in D2J osteoblasts at days 14 and 21 (Figure 6D). We then
examined early osteogenesis markers in osteoblasts of adult
D2J and D2J/Gpnmbþmice differentiated for 7 days. First, we
tested Runt-related transcription factor 2 (Runx2), which is
crucial for early osteoblastogenesis.26,27 Interestingly, Runx2ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Differentiation of primary calvarial
osteoblasts in neonatal D2J and D2J/Gpnmbþ
mice. A: Western blots of OA glycoprotein in pri-
mary osteoblasts cultured for 7 days. B: ELISA of
OA protein levels in osteoblast cell lysates,
normalized to total protein concentration. C:
Macro- and microscopic images of 14-day differ-
entiated osteoblasts stained for ALP (asterisks).
D: ALP activity in osteoblast matrix and cell ly-
sates. E: Macro- and microscopic images of 14-day
differentiated cultures stained for collagen (as-
terisks) with Sirius Red in D2J and D2J/Gpnmbþ.
F: Quantiﬁcation of Sirius Red collagen staining in
D2J and D2J/Gpnmbþ cultures. G: Percentage area
fraction of Sirius Redestained matrix in D2J and
D2J/Gpnmbþ cultures. Data are expressed as
means SEM. *P < 0.05, **P< 0.01. Scale barZ
100 mm.
Gpnmb Mutation Decreases Bone Formationgene expression was down-regulated in D2J osteoblasts
(Figure 6E). Next, we examined other transcription factors,
includingmuscle segment homeobox (Msx2), which functions
as a repressor for Runx2 promoter activity.28,29 Surprisingly,
Msx2 expression was up-regulated in D2J osteoblasts
(Figure 6F). In addition, Col1 gene expression was decreased
in D2J osteoblasts, compared to D2J/Gpnmbþ, at day 7
(Figure 6G).
To compare these ﬁndings with osteogenesis markers in
bones, we performed qPCR analyses of OA and bone for-
mation markers in calvaria and tibia of D2J and D2J/
Gpnmbþ mice. Gpnmb expression for OA was decreased in
calvaria and tibia of D2J mice (Figure 6H). qPCR analysis
of other bone formation markers in calvaria showed a
decrease of approximately 80% in Runx2 and ALP gene
expression in D2J mice (Figure 6, I and J). Col1 and OC
gene expressions were also decreased (by approximately
80%) in D2J mice (Figure 6, K and L). Taken together,
these data support the importance of OA during osteoblast
differentiation in vitro and osteogenesis in vivo.The American Journal of Pathology - ajp.amjpathol.orgLoss-ofeFunction Mutation in Gpnmb Decreases
Proliferation and Survival of Osteoblasts
To investigate the underlying mechanism or mechanisms
responsible for decreased differentiation of Gpnmb-mutant
osteoblasts, we examined the proliferation and survival of
osteoblasts in D2J and D2J/Gpnmbþ mice. Osteoblast pro-
liferation was decreased in D2J mice (Figure 7A). To conﬁrm
our results, we tested the expression of proliferating cell nu-
clear antigen (PCNA); this proliferation marker was approx-
imately 30% decreased in D2J osteoblasts (Figure 7B). To
examine whether adult mutant osteoblasts in D2J mice are
similar to neonatal calvarial mutant osteoblasts, we isolated
the osteoblasts from long bones of adult D2J and D2J/
Gpnmbþmice and tested their proliferation potential in vitro.
Proliferation of adult osteoblasts was decreased in D2J mice
after 72 hours (Figure 7C). Given that osteoblasts from D2J
mice proliferated less in vitro, and that osteoblast number was
increased in vivo, we asked whether some systemic factor or
factors in D2J are responsible for the high number of705
Figure 5 Mineralization of primary calvarial
osteoblasts in D2J and D2J/Gpnmbþ mice. A:
Macro- and microscopic images of 21-day differ-
entiated osteoblasts stained with Alizarin Red S for
calcium (asterisks). B: Quantiﬁcation of Alizarin
Red S calcium staining in D2J and D2J/Gpnmbþ
cultures. C: Calcium levels in total matrix and cell
lysates of D2J and D2J/Gpnmbþ osteoblasts. D:
Macro- and microscopic images of 21-day differ-
entiated osteoblasts stained with von Kossa stain-
ing for hydroxyapatite (black). Asterisks in
microscopic images indicate nodule border. Arrows
indicate unmineralized matrix. E: Nodule number
on an area basis. F: Nodule size. Data are expressed
as means  SEM. **P < 0.01, ***P < 0.001. Scale
barZ 100 mm.
Abdelmagid et alosteoblasts in vivo. We therefore tested the effects of serum
harvested from D2J and D2J/Gpnmbþ mice on osteoblast
proliferation. D2J/Gpnmbþ serum had no signiﬁcant effects
on either D2J/Gpnmbþ or D2J osteoblast proliferation;
conversely, D2J serum increased the proliferation of bothD2J
and D2J/Gpnmbþ osteoblasts (Figure 7D). These ﬁndings
suggest that some factor or factors in D2J serum stimulate
osteoblast proliferation.
Next, we examined whether Gpnmb mutation induces
cellular apoptosis in D2J osteoblasts in vitro. Our data
showed increased apoptosis of osteoblasts in D2J mice
(Figure 7E). In conﬁrmation, qPCR showed that proapop-
totic marker; Bax gene expression was increased by
approximately 40% in D2J mice (Figure 7F). Taken together,
these data suggest a cell-autonomous defect in proliferation
and survival of D2J osteoblasts.
Mutant OA Protein Does Not Induce ER Stress in
Osteoblasts
D2J mice are reported to have an early stop codon on Gpnmb
gene, with a truncated protein of 150 aa.5 We therefore
examined the levels of truncated OA protein by Western
blotting, which showed increased levels of the truncated OA
in osteoblasts of D2J mice (Figure 8A). Next, we examined
the localization of OA protein in D2J osteoblasts. OA was
immunodetected in a punctate, perinuclear pattern in D2J
mice, compared to ﬁne dispersion in D2J/Gpnmbþ osteo-
blasts (Figure 8B). Moreover, OA protein was mainly706condensed and colocalized with endoplasmic reticulum (ER)
in D2J osteoblasts.
Unfolded and truncated proteins are reported to increase
ER stress.30 To examine whether truncated OA protein in-
duces ER stress in D2J osteoblasts, we tested the levels of
GRP-78 protein, an ER stress marker.31 We did not ﬁnd any
signiﬁcant differences between D2J and D2J/Gpnmbþ os-
teoblasts differentiated for 7, 14, and 21 days (Figure 8C).
We also examined ER stress response in D2J osteoblasts
treated with tunicamycin, an ER stress inducer.32 Cell sur-
vival of D2J osteoblasts not treated with tunicamycin was
decreased at 48 and 72 hours, compared to D2J/Gpnmbþ
osteoblasts, as measured by MTT (Figure 8D); however,
there was no statistical difference in cell survival between
tunicamycin-treated D2J and D2J/Gpnmbþ osteoblasts at
any time point (Figure 8E). These data suggest that mutant
OA protein does not induce ER stress in D2J osteoblasts.
To further support our hypothesis, we examined the
morphology of ER ultrastructure in D2J osteoblasts by
transmission electron microscopy. For both D2J and D2J/
Gpnmbþ mice, there was no evidence of morphological ab-
normality of ER stress in osteoblasts either in vivo (Figure 8F)
or in vitro (Figure 8G). Collectively, these data showed no
evidence of ER stress in D2J osteoblasts.
TGF-b1 Signaling Is Activated in D2J Osteoblasts
To investigate the underlying mechanism or mechanisms
responsible for defective proliferation and differentiation ofajp.amjpathol.org - The American Journal of Pathology
Figure 6 qPCR analysis of Gpnmb gene
expression and bone formation markers in osteo-
blasts and bones of D2J and D2J/Gpnmbþ mice.
AeD: Expression of OA (A) and of osteoblast dif-
ferentiation markers ALP (B), Col1 (C), and OC (D)
in neonatal calvarial osteoblasts differentiated for
7, 14, or 21 days. EeG: Expression of the early
osteoblast differentiation markers Runx2 (E), Msx2
(F), and Col1 (G) in adult long-bone osteoblasts
differentiated for 7 days. HeL: Expression of OA in
calvaria and tibia (H) and expression of the bone
formation markers Runx2 (I), ALP (J), Col1 (K),
and OC (L) in calvaria of 8-week-old mice. Data are
expressed as means  SEM. n Z 3 (AeL).
*P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001 versus wild type. Gray bars, D2J;
black bars, D2J/Gpnmbþ. RU, relative units.
Gpnmb Mutation Decreases Bone FormationGpnmb-mutant osteoblasts, we used an osteogenesis array to
screen for 84 genes in D2J mice for possible differentially
expressed genes. Surprisingly, TGF-b1 and TGF-b re-
ceptors I, II, and III were up-regulated in calvaria of D2J
mice at 8 weeks, compared to D2J/Gpnmbþ (Figure 9A).
qPCR of TGF-b1 gene expression in neonatal calvarial os-
teoblasts revealed no difference between D2J and D2J/
Gpnmbþ mice (Figure 9B). Similar to the osteogenesis array
ﬁndings, TGF-b receptors I and II were approximately 50%
up-regulated in D2J osteoblasts (Figure 9, C and D).
Western blotting conﬁrmed the gene expression analysis,
showing no difference in TGF-b1 protein levels (Figure 9,
E and F) but a sixfold increase in TGF-b receptor II protein
(Figure 9, E and G) in D2J primary osteoblasts. Next, we
examined Smad activation downstream of TGF-b1 signaling
in serum-deprived osteoblasts. Although phosphorylation of
Smad-2 was increased by only approximately 20% in D2J
osteoblasts (Figure 9, H and I), phosphorylation of Smad-3
was increased by 3.5-fold (Figure 9, J and K). Taken
together, these data suggest that TGF-b receptors and
p-Smademediated signaling are activated in D2J osteoblasts.Discussion
Our initial interest in the role of OA in osteogenesis
emerged from our previous studies showing strong evidence
of the positive effects of OA on osteoblast differentiationThe American Journal of Pathology - ajp.amjpathol.organd function in vitro7e9 and in vivo.14,15 We sought to
further characterize the anabolic role of OA in bone using a
mouse model with a natural nonsense mutation in the
Gpnmb gene. Because of this mutation, the D2J mouse is a
unique animal model for examining the skeletal phenotype.
Loss of function due to homozygous mutation of Gpnmb
alleles in D2J resulted in substantial loss of bone mass,
based on micro-CT ﬁndings. It is important to notice the
consistent decrease in bone mass of D2J mice after 16
weeks of age. On the other hand, the sustained increase in
bone mass of the wild-type mice from 4 to 8 weeks of age
can be explained by the normal physiological bone growth
at this age. By contrast, D2J mice showed only a slight
increase in bone mass from 4 to 8 weeks, indicating a sig-
niﬁcant deﬁcit in osteogenesis. Serum ELISA of OA and the
bone-formation markers ALP and OC also were markedly
decreased, despite increased number of D2J osteoblasts
in vivo. Moreover, bone dynamic analyses of mineral
apposition and bone formation rates supported the decreased
function of D2J osteoblasts. Taken together, these ﬁndings
indicate that osteoblast function is deteriorated in the D2J
mouse due to absence of OA.
The fact of increased osteoblast number of D2J mice might
indicate that OA negatively regulates osteoblast proliferation
in vivo. Others have reported that OA (alias DC-HIL) sup-
presses the proliferation of cutaneous cell lymphoma through
binding to syndecan-4 and trapping TGF-b1 on the cell
surface33 and, moreover, OA attenuates cell proliferation and707
Figure 7 Proliferation and survival of primary osteoblasts in D2J and
D2J/Gpnmbþ mice. A: Proliferation assay measured by quantitation of
ﬂuorescence-labeled DNA in neonatal calvarial osteoblasts cultured in 10%
FBS and measured at 24, 48, and 72 hours. B: qPCR analysis of proliferating
cell nuclear antigen (PCNA) in 3-day proliferating osteoblasts. C: Prolifer-
ation assay of D2J and D2J/Gpnmbþ adult long-bone osteoblasts measured
at 24, 48, and 72 hours. D: Proliferation assay of osteoblasts cultured in
10% mouse serum for 24 hours. E: Apoptosis assay measured by quanti-
tation of caspase-3/7 luminescence of osteoblasts cultured in 2.5% FBS
and measured at 24, 48, and 72 hours. F: qPCR analysis of apoptosis
regulator Bax in osteoblasts cultured in 2.5% FBS serum for 3 days. Data are
expressed as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001. RLU, relative luminescence units.
Abdelmagid et alinvasion of prostate carcinoma cells by dysregulating the
tumor suppressor gene p53.34 These reports could explain the
increased osteoblast number in D2J mice due to lack of
Gpnmb. By contrast, in vitro testing showed that proliferation
of D2J osteoblasts was diminished, compared to D2J/
Gpnmbþ, suggesting that other factors might control the cell
proliferation in vivo and that these factors are absent in os-
teoblasts, cultured in vitro. Interestingly, proliferation of D2J
osteoblasts increased signiﬁcantly when treated with D2J
serum in vitro. Taken together, these ﬁndings suggest the
presence of systemic factors in sera of D2J mice that drive the
increase in osteoblast proliferation in vivo.
In support of our hypothesis, an osteogenesis proﬁling
array revealed an increase in gene expression of TGF-b1
and TGF-b receptors I, II, and III in D2J calvarial bone,
compared to the wild type. TGF-b1 is a secreted growth
factor reported to modulate proliferation and differentiation
of osteoprogenitor cells into osteoblasts.35 Although osteo-
blasts secrete several TGF-b isoforms (TGF-b1, -b2, -b3),
the TGF-b1 isoform accounts for more than 80% and up to
90% of the total TGF-b in the bone matrix.36,37 Furthermore,708Smad-2 and -3 were signiﬁcantly activated in D2J osteoblasts.
Activation of Smad-2/3 is reported to mediate TGF-b inhib-
itory effects on osteoblast proliferation, which might explain
in part the proliferation deﬁcit of D2J osteoblasts in vitro38
(although it cannot yet explain the increased osteoblasto-
genesis in D2J mice in vivo). Interestingly, TGF-b1 has been
well documented to stimulate proliferation and to promote
migration of osteoprogenitors to the sites of bone remodeling
through a Smad-independent PI3K/AKT pathway.39e43 Such
mechanisms warrant further investigation. On the other hand,
the sustained presence of TGF-b1 has been shown to inhibit
osteoblast differentiation and the corresponding mineral con-
tents,44e46 which might contribute to the decreased bone mass
observed in D2J mice. Taken together, these data suggest a
possible relationship between OA and TGF-b1 in modulating
osteoblast proliferation and differentiation.
In terms of cell survival, Gpnmb mutation increased
apoptosis and decreased survival of D2J osteoblasts through
activation of caspases 3/7, which might explain the defective
osteoblast differentiation in D2J. Caspases 1, 2, 3, 6, 7, and 8
regulate cell differentiation and activity,47e51 and speciﬁcally
caspases 2, 3, and 8 regulate osteoblast differentiation by
arresting cell proliferation atG0/G1 in the cell cycle.52 It would
be interesting to test the activity of caspases 2, 3, and 8 in
differentiating D2J osteoblasts lacking OA. Moreover, trun-
cated proteins often are expected to bemisfolded, andmight be
degraded through proteasomes or retained in ER, inducing ER
stress response.53e55 In the present study, truncatedOAprotein
did not induce ER stress in D2J osteoblasts. Moreover, ER
stress markers are reported to be induced during osteoblast
differentiation,56,57 thatmight explain the temporally increased
levels of the ER stress marker GRP-78, with no signiﬁcant
differences in between D2J and D2J/Gpnmbþ osteoblasts. ER
stresseinduced osteoblast apoptosis has also been documented
in a mouse model of osteogenesis imperfecta, a condition
mouse characterized by decreased bone mass and multiple
fractures.58 In this studyD2Josteoblasts showed increasedcell-
apoptosis, compared to D2J/Gpnmbþ, however, cell apoptosis
was independent of ER stress.
The present ﬁndings of decreased osteoblast differentia-
tion in D2J mice (mutant Gpnmb alleles) are consistent with
ﬁndings from our previous studies using a loss-ofefunction
approach of Gpnmb in MC3T3.E1 preosteoblasts, in which
Gpnmb down-regulation halted osteoblast differentiation
in vitro; by contrast, a gain-of-function approach of Gpnmb
expedited osteoblast differentiation and matrix mineraliza-
tion in vitro.7,8 Next, examining the expression of OA
protein showed that truncated OA existed mostly peri-
nuclearly and colocalized with ER in D2J osteoblasts, yet
we were able to detect low levels of OA extracellularly in
sera and bones of D2J mice (Figure 2, A and B). These
ﬁndings suggest that D2J osteoblasts lacking the aa
sequence 151-562 produce low amounts of the truncated
OA protein (aa sequence: 23-150) and that is secreted
extracellularly; however, the mechanism is not yet under-
stood. Another group has reported a similar phenomenon, inajp.amjpathol.org - The American Journal of Pathology
Figure 8 ER Stress in primary osteoblasts of D2J and D2J/Gpnmbþ mice. A: Western blots of native OA protein (approximately 65 kDa) and truncated OA
protein (approximately 15 kDa) in primary osteoblasts cultured for 3 days. B: Immunoﬂuorescence detection of OA colocalizing with rER) in osteoblasts.
Primary osteoblasts were cultured in chamber slides, ﬁxed, stained with anti-ER (calnexin) and anti-OA antibodies, and counterstained with DAPI for nuclei.
Images were captured with a ﬂuorescence microscope using separate excitation ﬁlters for OA (green), rER (red), and nucleus (blue), and merged images were
generated. C: Western blots of the ER stress marker Grp-78 in differentiated osteoblasts at days 7, 14, and 21. The Grp-78/actin relative densitometry ratios are
shown below the Grp-78 blots. D and E: MTT survival assay at 24, 48 and 72 hours in osteoblasts cultured in 10% FBS only (D) and in osteoblasts treated with 5
mg/mL tunicamycin (TM). F and G: Transmission electron microscopy images of osteoblast ultrastructure in vivo (F) and in vitro (G), showing rER, nucleus (Nc),
mitochondria (M), nucleolus (asterisk), and osteoid bone (Ost). Insets: Intact rER. Data are expressed as means  SEM. ***P < 0.001, ****P < 0.0001. Scale
bars: 2000 nm (F and G); 500 nm (insets, F and G). Original magniﬁcation: 200 (B).
Gpnmb Mutation Decreases Bone Formationwhich truncated mutant Fukutin-related protein (FKRP)
lacking the C-terminal 185 aa because of nonsense mutation
is secreted as efﬁciently as the normal FKRP by CHO
cells.59 Decreased production of the truncated mutant OA
protein by D2J osteoblasts could be explained in part by
enzymatic degradation through proteasome. In a similar
mechanism, mutant ﬁbroblast growth factor receptor-2
(FGFR2), which is responsible for craniosynostosis syn-
drome, has increased trafﬁcking into lysosomes and pro-
teasomes for degradation.60 As we cannot exclude the
possibility of residual function of the truncated OA, that
might explain the residual osteoblast differentiation
observed in D2J cultures.
Another possibility is that loss-of-function mutation of
Gpnmb suppressed the osteogenic effects of other growth
factors, such as bone morphogenetic proteins (BMPs), on
D2J osteoblasts. We have previously shown that OA acts as a
downstream mediator of BMP-2 on osteoblasts and that
knocking downGpnmb partially decreased the effects of BMP-
2 on osteoblast differentiation and function.9,61 Next, we re-
ported that OA glycoprotein consists of different domains
(including extracellular, transmembrane, and cytoplasmicThe American Journal of Pathology - ajp.amjpathol.orgdomains), as well as subdomains with different functions [eg,
signal peptide, polycystic kidney domain (PKD), proline rich
repeat domain (PRRD), RGD integrin-binding motif, and
dileucine-based sorting sequence].7,62 Several reports have
shown the importance of PKD in adhesive proteineprotein and
proteinecarbohydrate interactions, and in protecting the cell
from extreme environment.63,64 Other studies have elucidated
the importance of RGD binding motif in adhesion of various
cell types,65e70 and the role of PRRD in formation of mela-
nosomes and melanocyte function.71
The intrinsic defect observed in differentiated D2J oste-
oblasts could be due to a functional domain that is missing
or truncated in mutant OA protein (in contrast to normal
differentiated D2J/Gpnmbþ osteoblasts, with all domains
of the wild-type OA protein intact). In D2J osteoblast cul-
tures, we observed a decreased amount of Col1 and calcium
in matrix that did not match the marked decrease in osteo-
blast nodule size and number after 21 days. Moreover,
osteoblast nodules in D2J showed incomplete mineraliza-
tion. These data suggest that the mutant OA protein in D2J
mice not only diminished early osteoblast differentiation but
also reduced their function in vitro.709
Figure 9 TGF-b1 signaling in primary osteoblasts of D2J and D2J/Gpnmbþ mice. A: Osteogenesis array for TGF-b1, TGF-b receptors I, II, and III (TGF-b R.I,
TGF-b R.II, and TGF-b R.III) measured in calvaria of 8-week-old mice. BeD: qPCR analyses of TGF-b1 (B), TGF-b R.I (C), and TGF-b R.II (D) in calvarial primary
osteoblasts. E: Western blots of TGF-b1 and TGF-b R.II in primary osteoblasts. F and G: Corresponding densitometry for TGF-b1 (F) and TGF-b R.II (G) relative
to actin. HeK: Western blots of p-Smad-2 (H) and p-Smad-3 (J), with the corresponding densitometry relative to Smad-2 (I) and Smad-3 (K). Data are
expressed as means  SEM. *P < 0.05, **P < 0.01. Gray bars, D2J; black bars, D2J/Gpnmbþ.
Abdelmagid et alThese ﬁndings also suggest the importance of other do-
mains and subdomains of the wild-type OA protein
sequence (151 to 562 aa) in osteoblast differentiation and
function, in comparison to the truncated domains in mutant
OA protein sequence (23 to 150 aa). In a previous study, we
showed the positive role of OA C-terminalederived peptide
(538 to 556 aa), that is absent in mutant OA, in osteoblast
differentiation and matrix mineralization.72 Introducing
different functional domains of OA into D2J osteoblasts
could help to better characterize the importance of each
domain in osteoblast differentiation and function.
The highest increase in Gpnmb gene expression was
detected in terminally differentiated osteoblasts of both D2J
and D2J/Gpnmbþ mice, despite marked decrease in Gpnmb
in D2J osteoblasts. Furthermore, Gpnmb expression was
higher in calvarial bone of both D2J and D2J/Gpnmbþ mice,
compared to tibia, despite lower Gpnmb in D2J bones
overall. These ﬁndings may suggest a role of OA in intra-
membranous ossiﬁcation, in which osteoprogenitor cells
differentiate from MSCs.73 Other gene mutations affecting
intramembranous ossiﬁcation such as FGFR1, FGFR2, and
FGFR3 are reported to be associated with craniosynostosis
(ie, abnormal craniofacial development with premature fu-
sions of the cranial sutures).74e76 It would be interesting to
characterize any abnormality of the craniofacial development
in D2J mice.710We reported previously on the defective differentiation of
bone marrowederived MSCs into osteoblasts of D2J mice,
compared to D2J/Gpnmbþ.7 In the present study, we
observed that a periosteal thickness of D2J femur, which is
the source of MSCs,77 that was thinner led to decreased bone
formation overall compared to wild-type. Moreover, we
noticed increased numbers of adipocytes in the marrow
cavity of the D2J femur, suggesting more adipogenic and less
osteogenic differentiation of MSCs. That could explain, at
least in part, the resultant bone mass in D2J mice. It would be
important to study the adipogenic differentiation in parallel
with osteogenic differentiation of D2J MSCs. Taken
together, the present ﬁndings, consistent with our previous
reports,7e9,11 point to a signiﬁcant role for OA in regulating
osteoblast differentiation from MSCs.
Several other matrix proteins are important in osteo-
genesis, and loss-ofefunction mutations in these proteins
lead to human diseases. An example is truncated Col1
resulted from genomic deletion of ﬁve to eight exons in the
triple helical domain. This truncated Col1 leads to osteo-
genesis imperfecta, a potentially lethal disorder characterized
by brittle bones, high bone deformities, high fragility, and
increased fracture risk.78 Another example is mutation in the
osteocalcin gene that leads to truncated protein and devel-
opment of Keutel syndrome, characterized by abnormal
cartilage calciﬁcation, peripheral pulmonary stenosis, andajp.amjpathol.org - The American Journal of Pathology
Gpnmb Mutation Decreases Bone Formationmidfacial hypoplasia.79 Although our present ﬁndings
strongly suggest an important role for OA in osteogenesis,
based on the observed decreased bone mass and osteoblast
differentiation in the Gpnmb-mutant D2J mice, we cannot
exclude a role for OA in differentiation of other cell types
such as osteoclasts. In one study, increased Gpnmb expres-
sion colocalized with b3 heteropolymeric complex during
osteoclast differentiation.16 The same research group also
showed that overexpression of Gpnmb in osteoclasts under
tartrate-resistant acid phosphatase (TRAP) promoter led to
increased bone resorptive activity.80
Consistent with those reports, we expect that the Gpnmb
mutation would inhibit osteoclast function, which might
explain the low bone turnover in D2J mice. On the other
hand, the physiological role of osteoclasts in bone remodel-
ing was marked in D2J/Gpnmbþ wild-type mice by a notable
decrease in bone mass from 8 to 16 weeks old,81 consistent
with similar decrease in bone mass in other mouse strains of
the same age group. Interestingly, in the present study bone
mass of D2J mice did not show signiﬁcant changes from 8 to
16 weeks of age, suggestive of halted bone remodeling due to
osteoclast functional defect. Bone resorption markers
RANKL and OPG were not relevant, suggesting no differ-
ence in the total number of osteoclasts between D2J and D2J/
Gpnmbþ mice in vivo.
In ongoing work with D2J mice, we are studying in depth
the effect of Gpnmb mutation on osteoclast differentiation
and their bone resorptive activity. Generation of other
genetically engineered mouse models, such as osteoblast-
speciﬁc knockout of Gpnmb or transgenic Gpnmb, may
help us to understand and identify the direct effects and the
possible mechanism or mechanisms of action of OA in
osteoblast differentiation and their function in postnatal
bone formation.
References
1. Suh TT, Lyles KW: Osteoporosis considerations in the frail elderly.
Curr Opin Rheumatol 2003, 15:481e486
2. Mori S: [Contribution of bone quality to fracture risk]. Japanese. Clin
Calcium 2004, 14:33e38
3. Safadi FF, Xu J, Smock SL, Rico MC, Owen TA, Popoff SN:
Cloning and characterization of osteoactivin, a novel cDNA
expressed in osteoblasts. J Cell Biochem 2001, 84:12e26
4. Shikano S, Bonkobara M, Zukas PK, Ariizumi K: Molecular cloning
of a dendritic cell-associated transmembrane protein, DC-HIL, that
promotes RGD-dependent adhesion of endothelial cells through
recognition of heparan sulfate proteoglycans. J Biol Chem 2001, 276:
8125e8134
5. AndersonMG, Smith RS, Hawes NL, Zabaleta A, Chang B,Wiggs JL,
John SW: Mutations in genes encoding melanosomal proteins cause
pigmentary glaucoma in DBA/2J mice. Nat Genet 2002, 30:81e85
6. Bandari PS, Qian J, Yehia G, Joshi DD, Maloof PB, Potian J, Oh HS,
Gascon P, Harrison JS, Rameshwar P: Hematopoietic growth factor
inducible neurokinin-1 type: a transmembrane protein that is similar
to neurokinin 1 interacts with substance P. Regul Pept 2003, 111:
169e178
7. Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-
Hisijara I, Selim AH, Anderson MG, Owen TA, Popoff SN,The American Journal of Pathology - ajp.amjpathol.orgSafadi FF: Osteoactivin, an anabolic factor that regulates osteoblast
differentiation and function. Exp Cell Res 2008, 314:2334e2351
8. Selim AA, Abdelmagid SM, Kanaan RA, Smock SL, Owen TA,
Popoff SN, Safadi FF: Anti-osteoactivin antibody inhibits osteoblast
differentiation and function in vitro. Crit Rev Eukaryot Gene Expr
2003, 13:265e275
9. Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popoff SN,
Safadi FF: Osteoactivin acts as downstream mediator of BMP-2 effects
on osteoblast function. J Cell Physiol 2007, 210:26e37
10. Owen TA, Smock SL, Prakash S, Pinder L, Brees D, Krull D,
Castleberry TA, Clancy YC, Marks SC Jr, Safadi FF, Popoff SN:
Identiﬁcation and characterization of the genes encoding human and
mouse osteoactivin. Crit Rev Eukaryot Gene Expr 2003, 13:205e220
11. Abdelmagid SM, Barbe MF, Hadjiargyrou M, Owen TA,
Razmpour R, Rehman S, Popoff SN, Safadi FF: Temporal and spatial
expression of osteoactivin during fracture repair. J Cell Biochem
2010, 111:295e309
12. Arosarena OA, Del Carpio-Cano FE, Dela Cadena RA, Rico MC,
Nwodim E, Safadi FF: Comparison of bone morphogenetic protein-2
and osteoactivin for mesenchymal cell differentiation: effects of bolus
and continuous administration. J Cell Physiol 2011, 226:2943e2952
13. Raynaud CM, Maleki M, Lis R, Ahmed B, Al-Azwani I, Malek J,
Safadi FF, Raﬁi A: Comprehensive characterization of mesenchymal
stem cells from human placenta and fetal membrane and their
response to osteoactivin stimulation. Stem Cells Int 2012, 2012:
658356
14. Singh M, Del Carpio-Cano F, Belcher JY, Crawford K, Frara N,
Owen TA, Popoff SN, Safadi FF: Functional roles of osteoactivin in
normal and disease processes. Crit Rev Eukaryot Gene Expr 2010,
20:341e357
15. Bateman JP, Safadi FF, Susin C, Wikesjö UM: Exploratory study on
the effect of osteoactivin on bone formation in the rat critical-size
calvarial defect model. J Periodontal Res 2012, 47:243e247
16. Sheng MH, Wergedal JE, Mohan S, Lau KH: Osteoactivin is a novel
osteoclastic protein and plays a key role in osteoclast differentiation
and activity. FEBS Lett 2008, 582:1451e1458
17. Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A,
Savinova O, Roderick TH, Heckenlively JR, Davisson MT, John SW:
Interacting loci cause severe iris atrophy and glaucoma in DBA/2J
mice. Nat Genet 1999, 21:405e409
18. Willott JF, Bosch JV, Shimizu T, Ding DL: Effects of exposing
DBA/2J mice to a high-frequency augmented acoustic environment
on the cochlea and anteroventral cochlear nucleus. Hear Res 2006,
216-217:138e145
19. Willott JF, Bross LS, McFadden S: Ameliorative effects of exposing
DBA/2J mice to an augmented acoustic environment on histological
changes in the cochlea and anteroventral cochlear nucleus. J Assoc
Res Otolaryngol 2005, 6:234e243
20. Anderson MG, Smith RS, Savinova OV, Hawes NL, Chang B,
Zabaleta A, Wilpan R, Heckenlively JR, Davisson M, John SW:
Genetic modiﬁcation of glaucoma associated phenotypes between
AKXD-28/Ty and DBA/2J mice. BMC Genet 2001, 2:1
21. Howell GR, Libby RT, Marchant JK, Wilson LA, Cosma IM,
Smith RS, Anderson MG, John SW: Absence of glaucoma in DBA/2J
mice homozygous for wild-type versions of Gpnmb and Tyrp1. BMC
Genet 2007, 8:45
22. Safadi FF, Hermey DC, Popoff SN, Seifert MF: Skeletal resistance to
1,25-dihydroxyvitamin D3 in osteopetrotic rats. Endocrine 1999, 11:
309e319
23. Bakker AD, Klein-Nulend J: Osteoblast isolation from murine
calvaria and long bones. Methods Mol Biol 2012, 816:19e29
24. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K,
Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K,
Gillespie MT, Martin TJ, Suda T: Osteoblasts/stromal cells stimulate
osteoclast activation through expression of osteoclast differentiation
factor/RANKL but not macrophage colony-stimulating factor: re-
ceptor activator of NF-kappa B ligand. Bone 1999, 25:517e523711
Abdelmagid et al25. Watanabe Y, Namba A, Aida Y, Honda K, Tanaka H, Suzuki N,
Matsumura H, Maeno M: IL-1beta suppresses the formation of os-
teoclasts by increasing OPG production via an autocrine mechanism
involving celecoxib-related prostaglandins in chondrocytes. Media-
tors Inﬂamm 2009, 2009:308596
26. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E:
Multiple signaling pathways converge on the Cbfa1/Runx2 tran-
scription factor to regulate osteoblast differentiation. Connect Tissue
Res 2003, 44(Suppl 1):109e116
27. Karsenty G, Ducy P, Starbuck M, Priemel M, Shen J, Geoffroy V,
Amling M: Cbfa1 as a regulator of osteoblast differentiation and
function. Bone 1999, 25:107e108
28. Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E:
Regulation of the activity of the transcription factor Runx2 by two
homeobox proteins, Msx2 and Dlx5. Genes Cells 2001, 6:851e856
29. Takahashi T, Kato S, Suzuki N, Kawabata N, Takagi M: Autor-
egulatory mechanism of Runx2 through the expression of transcrip-
tion factors and bone matrix proteins in multipotential mesenchymal
cell line, ROB-C26. J Oral Sci 2005, 47:199e207
30. Boot-Handford RP, Briggs MD: The unfolded protein response and
its relevance to connective tissue diseases. Cell Tissue Res 2010, 339:
197e211
31. Lee AS: The ER chaperone and signaling regulator GRP78/BiP as a
monitor of endoplasmic reticulum stress. Methods 2005, 35:373e381
32. Jang WG, Kim EJ, Koh JT: Tunicamycin negatively regulates BMP2-
induced osteoblast differentiation through CREBH expression in
MC3T3E1 cells. BMB Rep 2011, 44:735e740
33. Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr., Ariizumi K:
Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan
sulfate moieties that suppress T-cell activation by binding DC-HIL and
trapping TGF-beta on the cell surface. Blood 2011, 117:3382e3390
34. Tsui KH, Chang YL, Feng TH, Chang PL, Juang HH: Glycoprotein
transmembrane nmb: an androgen-downregulated gene attenuates cell
invasion and tumorigenesis in prostate carcinoma cells. Prostate 2012,
72:1431e1442
35. Dallas SL, Rosser JL, Mundy GR, Bonewald LF: Proteolysis of latent
transforming growth factor-beta (TGF-beta)-binding protein-1 by
osteoclasts. A cellular mechanism for release of TGF-beta from bone
matrix. J Biol Chem 2002, 277:21352e21360
36. Gatherer D, Ten Dijke P, Baird DT, Akhurst RJ: Expression of TGF-
beta isoforms during ﬁrst trimester human embryogenesis. Develop-
ment 1990, 110:445e460
37. Thorp BH, Anderson I, Jakowlew SB: Transforming growth factor-
beta 1, -beta 2 and -beta 3 in cartilage and bone cells during endo-
chondral ossiﬁcation in the chick. Development 1992, 114:907e911
38. Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res
2009, 19:128e139
39. Mu Y, Gudey SK, Landström M: Non-Smad signaling pathways. Cell
Tissue Res 2012, 347:11e20
40. Li X, Huang X, Qi ZL, Wang W: [Transforming growth factor-beta
superfamily in the regulation of new bone formation]. Chinese.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2002, 16:126e129
41. Liu P, Oyajobi BO, Russell RG, Scutt A: Regulation of osteogenic
differentiation of human bone marrow stromal cells: interaction be-
tween transforming growth factor-beta and 1,25(OH)(2) vitamin D(3)
In vitro. Calcif Tissue Int 1999, 65:173e180
42. Kessler S, Kastler S, Mayr-Wohlfart U, Puhl W, Günther KP:
Stimulation primärer Osteoblastenkulturen mit rh-TGF-b, rh-bFGF,
rh-BMP 2 und rx-BMP 4 in einem In-vitro-Modell [Stimulation of
primary osteoblast cultures with rh-TGF-beta, rh-bFGF, rh-BMP 2
and rx-BMP 4 in an in vitro model]. Orthopade 2000, 29:107e111
43. Ingram RT, Bonde SK, Riggs BL, Fitzpatrick LA: Effects of trans-
forming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3
on the function, cytochemistry and morphology of normal human
osteoblast-like cells. Differentiation 1994, 55:153e163
44. Lian N, Lin T, Liu W, Wang W, Li L, Sun S, Nyman JS, Yang X:
Transforming growth factor b suppresses osteoblast differentiation712via the vimentin activating transcription factor 4 (ATF4) axis. J Biol
Chem 2012, 287:35975e35984
45. Lian JB, Stein GS: The developmental stages of osteoblast growth
and differentiation exhibit selective responses of genes to growth
factors (TGF beta 1) and hormones (vitamin D and glucocorticoids). J
Oral Implantol 1993, 19:95e105; discussion 36e37
46. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R: TGF-beta-
induced repression of CBFA1 by Smad3 decreases cbfa1 and
osteocalcin expression and inhibits osteoblast differentiation. EMBO
J 2001, 20:2254e2272
47. Basu S, Rajakaruna S, Menko AS: Insulin-like growth factor
receptor-1 and nuclear factor kappaB are crucial survival signals that
regulate caspase-3-mediated lens epithelial cell differentiation initia-
tion. J Biol Chem 2012, 287:8384e8397
48. Chan G, Nogalski MT, Yurochko AD: Human cytomegalovirus
stimulates monocyte-to-macrophage differentiation via the temporal
regulation of caspase 3. J Virol 2012, 86:10714e10723
49. Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA: Caspase 3
activity is required for skeletal muscle differentiation. Proc Natl Acad
Sci USA 2002, 99:11025e11030
50. Gabet AS, Coulon S, Fricot A, Vandekerckhove J, Chang Y,
Ribeil JA, Lordier L, Zermati Y, Asnaﬁ V, Belaid Z, Debili N,
Vainchenker W, Varet B, Hermine O, Courtois G: Caspase-activated
ROCK-1 allows erythroblast terminal maturation independently of
cytokine-induced Rho signaling. Cell Death Diff 2011, 18:678e689
51. Rébé C, Cathelin S, Launay S, Filomenko R, Prévotat L,
L’Ollivier C, Gyan E, Micheau O, Grant S, Dubart-Kupperschmitt A,
Fontenay M, Solary E: Caspase-8 prevents sustained activation of
NF-kappaB in monocytes undergoing macrophagic differentiation.
Blood 2007, 109:1442e1450
52. Mogi M, Togari A: Activation of caspases is required for osteoblastic
differentiation. J Biol Chem 2003, 278:47477e47482
53. Ding WX, Yin XM: Sorting, recognition and activation of the mis-
folded protein degradation pathways through macroautophagy and
the proteasome. Autophagy 2008, 4:141e150
54. Hiller MM, Finger A, Schweiger M, Wolf DH: ER degradation of a
misfolded luminal protein by the cytosolic ubiquitin-proteasome
pathway. Science 1996, 273:1725e1728
55. Christis C, Fullaondo A, Schildknegt D, Mkrtchian S, Heck AJ,
Braakman I: Regulated increase in folding capacity prevents unfolded
protein stress in the ER. J Cell Sci 2010, 123:787e794
56. Saito A, Ochiai K, Kondo S, Tsumagari K, Murakami T,
Cavener DR, Imaizumi K: Endoplasmic reticulum stress response
mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in
osteoblast differentiation induced by BMP2. J Biol Chem 2011, 286:
4809e4818
57. Hamamura K, Yokota H: Stress to endoplasmic reticulum of mouse
osteoblasts induces apoptosis and transcriptional activation for bone
remodeling. FEBS Lett 2007, 581:1769e1774
58. Lisse TS, Thiele F, Fuchs H, Hans W, Przemeck GK, Abe K,
Rathkolb B, Quintanilla-Martinez L, Hoelzlwimmer G, Helfrich M,
Wolf E, Ralston SH, Hrabé de Angelis M: ER stress-mediated
apoptosis in a new mouse model of osteogenesis imperfecta. PLoS
Genet 2008, 4:e7
59. Lu PJ, Zillmer A, Wu X, Lochmuller H, Vachris J, Blake D,
Chan YM, Lu QL: Mutations alter secretion of fukutin-related pro-
tein. Biochim Biophys Acta 2010, 1802:253e258
60. Hatch NE, Hudson M, Seto ML, Cunningham ML, Bothwell M:
Intracellular retention, degradation, and signaling of glycosylation-
deﬁcient FGFR2 and craniosynostosis syndrome-associated
FGFR2C278F. J Biol Chem 2006, 281:27292e27305
61. Singh M, Del Carpio-Cano FE, Monroy MA, Popoff SN, Safadi FF:
Homeodomain transcription factors regulate BMP-2-induced osteoac-
tivin transcription in osteoblasts. J Cell Physiol 2012, 227:390e399
62. Selim AA: Osteoactivin bioinformatic analysis: prediction of novel
functions, structural features, and modes of action. Med Sci Monit
2009, 15:MT19eMT33ajp.amjpathol.org - The American Journal of Pathology
Gpnmb Mutation Decreases Bone Formation63. Bycroft M, Bateman A, Clarke J, Hamill SJ, Sandford R, Thomas RL,
Chothia C: The structure of a PKD domain from polycystin-1: im-
plications for polycystic kidney disease. EMBO J 1999, 18:297e305
64. Jing H, Takagi J, Liu JH, Lindgren S, Zhang RG, Joachimiak A,
Wang JH, Springer TA: Archaeal surface layer proteins contain beta
propeller, PKD, and beta helix domains and are related to metazoan
cell surface proteins. Structure 2002, 10:1453e1464
65. Kim SY, Oh HK, Ha JM, Ahn HY, Shin JC, Baek SH, Lim SC,
Joe YA: RGD-peptide presents anti-adhesive effect, but not direct
pro-apoptotic effect on endothelial progenitor cells. Arch Biochem
Biophys 2007, 459:40e49
66. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A,
Gougos A, Letarte M, Bernabeu C: Regulated expression on human
macrophages of endoglin, an Arg-Gly-Asp-containing surface anti-
gen. Eur J Immunol 1992, 22:393e397
67. Rezania A, Healy KE: Integrin subunits responsible for adhesion of
human osteoblast-like cells to biomimetic peptide surfaces. J Orthop
Res 1999, 17:615e623
68. Schofer MD, Boudriot U, Bockelmann S, Walz A, Wendorff JH,
Greiner A, Paletta JR, Fuchs-Winkelmann S: Effect of direct RGD
incorporation in PLLA nanoﬁbers on growth and osteogenic differ-
entiation of human mesenchymal stem cells. J Mater Sci Mater Med
2009, 20:1535e1540
69. van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S,
Löwik C: Integrins and osteoclastic resorption in three bone organ
cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides
during osteoclast formation. J Bone Miner Res 1994, 9:1021e1028
70. Wang X, Yan C, Ye K, He Y, Li Z, Ding J: Effect of RGD nano-
spacing on differentiation of stem cells. Biomaterials 2013, 34:
2865e2874
71. Hoashi T, Muller J, Vieira WD, Rouzaud F, Kikuchi K, Tamaki K,
Hearing VJ: The repeat domain of the melanosomal matrix protein
PMEL17/GP100 is required for the formation of organellar ﬁbers. J
Biol Chem 2006, 281:21198e21208The American Journal of Pathology - ajp.amjpathol.org72. Selim AA, Castaneda JL, Owen TA, Popoff SN, Safadi FF: The role
of osteoactivin-derived peptides in osteoblast differentiation. Med Sci
Monit 2007, 13:BR259eBR270
73. Ornitz DM, Marie PJ: FGF signaling pathways in endochondral and
intramembranous bone development and human genetic disease.
Genes Dev 2002, 16:1446e1465
74. Park WJ, Meyers GA, Li X, Theda C, Day D, Orlow SJ, Jones MC,
Jabs EW: Novel FGFR2 mutations in Crouzon and Jackson-Weiss
syndromes show allelic heterogeneity and phenotypic variability.
Hum Mol Genet 1995, 4:1229e1233
75. Ornitz DM: Regulation of chondrocyte growth and differentiation by
ﬁbroblast growth factor receptor 3. Novartis Found Symp 2001, 232:
63e76; discussion 80, 272e282
76. Muenke M, Schell U: Fibroblast-growth-factor receptor mutations in
human skeletal disorders. Trends Genet 1995, 11:308e313
77. Mara CS, Sartori AR, Duarte AS, Andrade AL, PedroMA, Coimbra IB:
Periosteum as a source of mesenchymal stem cells: the effects of TGF-
b3 on chondrogenesis. Clinics (Sao Paulo) 2011, 66:487e492
78. Mundlos S, Chan D, Weng YM, Sillence DO, Cole WG, Bateman JF:
Multiexon deletions in the type I collagen COL1A2 gene in osteo-
genesis imperfecta type IB. Molecules containing the shortened
alpha2(I) chains show differential incorporation into the bone and
skin extracellular matrix. J Biol Chem 1996, 271:21068e21074
79. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F,
Yuksel B, Gardiner RM, Chung E: Mutations in the gene encoding
the human matrix Gla protein cause Keutel syndrome. Nat Genet
1999, 21:142e144
80. Sheng MH, Wergedal JE, Mohan S, Amoui M, Baylink DJ, Lau KH:
Targeted overexpression of osteoactivin in cells of osteoclastic line-
age promotes osteoclastic resorption and bone loss in mice. PLoS
One 2012, 7:e35280
81. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL,
Majumdar S: Changes in bone structure and mass with advancing age in
the male C57BL/6J mouse. J Bone Miner Res 2002, 17:1044e1050713
